Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Marie Skłodowska-Curie Action · Running

TagTIC Target mining for the development of therapeutics against pathogen-induced cancers

Coordinator
Paris-Lodron-Universitat Salzburg, Austria
Runs
1 January 2027 to 31 December 2031
Status
Running
EU funding
€4.3m
Total cost
—
Partners
23 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311627

What the project is doing

In the project's own words, from its summary on CORDIS.

Gastrointestinal cancers, including gastric and colorectal cancer, are among the most prevalent and lethal malignancies worldwide. Growing evidence highlights the microbial agents Fusobacterium nucleatum, Helicobacter pylori, or Epstein-Barr Virus as prominent key drivers of cancer initiation and progression by disrupting epithelial signaling, promoting chronic inflammation, and evading immune surveillance. However, current therapeutic strategies and model systems rarely address pathogenic tumorigenesis or progression and altered drug efficacy in the presence of these pathogens, leaving a critical gap in the development of precise and preventive treatments.

TagTIC addresses this challenge through a systems medicine approach that integrates microbiology, cancer biology, drug discovery, and artificial intelligence. By using innovative preclinical organoid model systems that closely resemble patient conditions, TagTIC aims to decipher complex host-pathogen interactions at single-cell and spatial resolution and to address them therapeutically. Research will focus on: (i) identifying vulnerable molecular nodes involved in pathogen-associated cancers; (ii) developing novel strategies for lead discovery and treatment; (iii) generating and analyzing innovative ex vivo models using 2D/3D cultures, patient-derived organoids, and organ-on-chip technologies.

The network will train eleven Doctoral Candidates (DCs) towards translational leaders, capable of analyzing and solving complex biomedical needs with innovative strategies and approaches. DCs will follow a structured training program combining basic and translational science with cross-sectoral exposure to academia and industry. The collaboration between nine beneficiaries and 14 associated partners ensures a strong curriculum, interdisciplinary mentorship, and international mobility to empower DCs for careers in academia, biotech, pharma, and socio-economic sectors across Europe.

Topics

Who is involved

OrganisationCityCountryRole
Paris-Lodron-Universitat SalzburgSalzburgAustriaCoordinator
Gemeinnutzige Salzburger Landeskliniken BetriebsgesellschaftSalzburgAustriaAssociatedpartner
Molecular Devices (Austria) GmbHUrstein bei HalleinAustriaAssociatedpartner
Tissuegnostics GmbHWienAustriaParticipant
G2L Services LimitedetobicokeCanadaAssociatedpartner
Abberior Instruments GmbHGottingenGermanyAssociatedpartner
Deutsches Krebsforschungszentrum HeidelbergHeidelbergGermanyParticipant
Evident Europe GmbH - Headquarter EMEA - GermanyHamburgGermanyAssociatedpartner
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyParticipant
Immunotools GmbHFriesoytheGermanyAssociatedpartner
Invigate GmbHJenaGermanyAssociatedpartner
MyxoTech GmbHSaarbrueckenGermanyAssociatedpartner
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyAssociatedpartner
Technische Universitaet MuenchenMuenchenGermanyAssociatedpartner
Universitat Des SaarlandesSaarbruckenGermanyParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
Cobiomic Bioscience SLCordobaSpainAssociatedpartner
Scienseed SLMadridSpainAssociatedpartner
Universidad Autonoma De MadridMadridSpainParticipant
Universita Degli Studi Di Roma La SapienzaRomaItalyParticipant
Uniwersytet GdanskiGdanskPolandParticipant
DeepMirror LtdCambridgeUnited KingdomAssociatedpartner
Meso Scale Diagnostics, LLC.Rockville, MDUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI